share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  08/01 07:11
Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of 12,000,000 options due to their expiry without exercise or conversion. The options, identified by the ASX security code ATHAAF and expiring on July 31, 2024, had an exercise price of $0.07. This event was officially reported in a Form 6-K filed with the SEC for the month of August 2024. Following the cessation of these securities, Alterity Therapeutics provided an update on its issued capital, which includes various classes of securities and options with different expiry dates and exercise prices. The company's ordinary fully paid shares total 5,320,336,118, and there are several other options with expiry dates ranging from August 2024 to March 2029. The cessation of the ATHAAF options has not involved any consideration from the entity.
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of 12,000,000 options due to their expiry without exercise or conversion. The options, identified by the ASX security code ATHAAF and expiring on July 31, 2024, had an exercise price of $0.07. This event was officially reported in a Form 6-K filed with the SEC for the month of August 2024. Following the cessation of these securities, Alterity Therapeutics provided an update on its issued capital, which includes various classes of securities and options with different expiry dates and exercise prices. The company's ordinary fully paid shares total 5,320,336,118, and there are several other options with expiry dates ranging from August 2024 to March 2029. The cessation of the ATHAAF options has not involved any consideration from the entity.
開發階段企業Alterity Therapeutics宣佈,由於到期未行權或轉換,其中1200萬期權已經停止。這些期權由ASX證券代碼ATHAAF標識,到期日爲2024年7月31日,行使價格爲0.07美元。這一事件在2024年8月的SEC 6-K表格中正式報道。在這些證券停止後,Alterity Therapeutics提供了其已發行資本的更新,包括具有不同到期日和行使價格的各類證券和期權。該公司的普通全額支付股票總計5,320,336,118股,還有其他多種到期日從2024年8月到2029年3月的期權。ATHAAF期權的停止未涉及該實體的任何考慮。
開發階段企業Alterity Therapeutics宣佈,由於到期未行權或轉換,其中1200萬期權已經停止。這些期權由ASX證券代碼ATHAAF標識,到期日爲2024年7月31日,行使價格爲0.07美元。這一事件在2024年8月的SEC 6-K表格中正式報道。在這些證券停止後,Alterity Therapeutics提供了其已發行資本的更新,包括具有不同到期日和行使價格的各類證券和期權。該公司的普通全額支付股票總計5,320,336,118股,還有其他多種到期日從2024年8月到2029年3月的期權。ATHAAF期權的停止未涉及該實體的任何考慮。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息